Winblad et al.
(
27
)
study 1
|
2001–2003
|
Multiple sites in South America, North America, Europe, Australia, New Zealand, Israel
|
Galantamine
16–24 mg, 96 wk
|
990
|
Cognition (ADAS), function, mortality, bradycardia, diarrhea, falls, headaches, nausea, SAEs
|
Winblad et al.
(
27
)
study 2
|
2001–2003
|
Multiple sites in South America, North America, Europe, Australia, New Zealand, Israel
|
Galantamine
16–24 mg, 96 wk
|
1058
|
Cognition (ADAS), function, mortality, bradycardia, diarrhea, falls, headaches, nausea, SAEs
|
Özenli et al.
(
28
)
|
2002–2004
|
Turkey
|
Donepezil
5–10 mg, 24 wk
|
51
|
Cognition (MMSE)
|
Salloway et al.
(
29
)
|
1999–2000
|
USA
|
Donepezil
5–10 mg, 24 wk
|
269
|
Cognition (ADAS, MMSE), diarrhea, nausea, SAEs, vomiting
|
Petersen et al.
(
30
)
(CR Schneider et al.
(
36
)
; Lu et al.
(
35
)
)
|
1999–2004
|
Canada
USA
|
Donepezil
5–10 mg, 156 wk
|
512
|
Cognition (ADAS, MMSE), diarrhea, nausea, vomiting
|
Doody et al.
(
31
)
|
2003–2007
|
USA
|
Donepezil, 5–10 mg, 48 wk
|
757
|
Cognition (ADAS, MMSE), behaviour, mortality, diarrhea, headaches, nausea, SAEs
|
Feldman et al.
(
32
)
(CR Ferris et al.
(
34
)
)
|
1999–2004
|
Multiple sites in North America and Europe
|
Rivastigmine, 3–12 mg, 208 wk
|
1014
|
Mortality, diarrhea, headaches, nausea, SAEs, vomiting
|
Ferris et al.
(
33
)
|
NR
|
USA
|
Memantine, 10–20 mg, 12.85 wk
|
60
|
SAEs
|